title: Comparison of neurogenic effects of fluoxetine, duloxetine and running in mice.
abstract: Hippocampal neurogenesis can be regulated by extrinsic factors, such as exercise and antidepressants. While there is evidence that the selective serotonin reuptake inhibitor (SSRI) fluoxetine enhances neurogenesis, the new dual serotonergic-noradrenergic reuptake inhibitor (SNRI) duloxetine has not been evaluated in this context. In addition, it is unclear whether effects of antidepressants and running on cell genesis and behavior are of similar magnitude in mice. Here, we assessed neurogenesis and open-field behavior in 2-month-old female C57Bl/6 mice after 28days of treatment with either fluoxetine (18mg/kg), duloxetine (2, 6 or 18mg/kg) or exercise. New cell survival, as measured by 5-bromo-2'-deoxyuridine (BrdU)-labeled cells, was enhanced by 200% in the running group only. Both running and fluoxetine, but not duloxetine, increased the percentage of new cells that became neurons. In the open-field test, animals treated with either drug spent less time in the center than controls and runners. In addition, fluoxetine treatment resulted in reduced locomotor activity. Together, these data show that the neurogenic response to exercise is much stronger than to antidepressants and imply a low likelihood that anxiolytic effects of these drugs are mediated by adult neurogenesis in C57Bl/6 mice.
authors.affiliation: Swammerdam Institute for Life Science-Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Marlatt
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Lucassen
authors.forename: Henriette
authors.initials: H
authors.lastname: van Praag
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D000068736:Duloxetine Hydrochloride; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology*; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D055495:Neurogenesis / Q000187:drug effects / Q000502:physiology; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D010805:Physical Conditioning, Animal / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013876:Thiophenes / Q000494:pharmacology*
chemical_list: D000068736:Duloxetine Hydrochloride; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes
references.citation: Neurosci Lett. 2001 Jul 27;308(1):25-8
references.pmid: 11445277
references.citation: J Gend Specif Med. 1998 Sep;1(1):21-7
references.pmid: 11279849
references.citation: Nat Neurosci. 1999 Mar;2(3):266-70
references.pmid: 10195220
references.citation: Neuromolecular Med. 2008;10(2):128-40
references.pmid: 18286389
references.citation: Mol Psychiatry. 2009 Sep;14(9):856-64
references.pmid: 19139747
references.citation: J Gend Specif Med. 2000 Mar-Apr;3(2):54-8
references.pmid: 11253247
references.citation: Acta Physiol Scand. 1989 Sep;137(1):1-13
references.pmid: 2678895
references.citation: Neuroscience. 2009 Oct 6;163(2):609-17
references.pmid: 19576966
references.citation: Curr Pharm Des. 2005;11(12):1475-93
references.pmid: 15892657
references.citation: Eur Neuropsychopharmacol. 2010 Jan;20(1):1-17
references.pmid: 19748235
references.citation: Nat Rev Neurosci. 2001 May;2(5):343-51
references.pmid: 11331918
references.citation: Pharmacol Biochem Behav. 2002 Apr;71(4):667-80
references.pmid: 11888558
references.citation: Pharmacol Biochem Behav. 2006 Sep;85(1):44-9
references.pmid: 16920181
references.citation: Neuron. 2002 Mar 28;34(1):13-25
references.pmid: 11931738
references.citation: Neuron. 2009 May 28;62(4):479-93
references.pmid: 19477151
references.citation: J Neurosci. 2000 Dec 15;20(24):9104-10
references.pmid: 11124987
references.citation: Am J Psychiatry. 2003 Aug;160(8):1516-8
references.pmid: 12900317
references.citation: J Neurosci. 2008 Feb 6;28(6):1374-84
references.pmid: 18256257
references.citation: Psychosom Med. 2007 Sep-Oct;69(7):587-96
references.pmid: 17846259
references.citation: J Comp Neurol. 2005 May 23;486(1):39-47
references.pmid: 15834963
references.citation: Arch Gen Psychiatry. 1987 Jan;44(1):69-76
references.pmid: 2432848
references.citation: Nature. 1995 Jan 12;373(6510):109
references.pmid: 7816089
references.citation: J Comp Neurol. 2008 Aug 1;509(4):372-81
references.pmid: 18512685
references.citation: Hippocampus. 2009 Oct;19(10):928-36
references.pmid: 19212941
references.citation: Neuroscience. 2000;101(2):305-12
references.pmid: 11074154
references.citation: Nat Rev Drug Discov. 2005 Sep;4(9):764-74
references.pmid: 16121130
references.citation: Brain Res. 2008 Sep 4;1228:14-9
references.pmid: 18616933
references.citation: Neuropsychopharmacology. 2009 May;34(6):1523-32
references.pmid: 19020498
references.citation: J Neurosci. 1997 Apr 1;17(7):2492-8
references.pmid: 9065509
references.citation: Eur J Neurosci. 2007 Dec;26(12):3395-401
references.pmid: 18052970
references.citation: Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13427-31
references.pmid: 10557337
references.citation: Psychopharmacology (Berl). 2009 May;203(4):753-62
references.pmid: 19104776
references.citation: Neuropsychopharmacology. 2007 Nov;32(11):2351-9
references.pmid: 17327885
references.citation: Neuroscience. 2007 Feb 9;144(3):1033-44
references.pmid: 17137724
references.citation: J Neurosci. 1996 Mar 15;16(6):2027-33
references.pmid: 8604047
references.citation: Nat Neurosci. 2007 Sep;10(9):1110-5
references.pmid: 17726477
references.citation: J Neurosci. 2009 Nov 18;29(46):14484-95
references.pmid: 19923282
references.citation: Neuron. 2008 Aug 14;59(3):399-412
references.pmid: 18701066
references.citation: J Abnorm Psychol. 1998 Feb;107(1):109-17
references.pmid: 9505043
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1321-30
references.pmid: 15085085
references.citation: Mol Psychiatry. 2000 May;5(3):262-9
references.pmid: 10889528
references.citation: J Pharmacol Exp Ther. 2010 Jan;332(1):266-73
references.pmid: 19828877
references.citation: Behav Brain Res. 2008 Sep 1;192(1):42-60
references.pmid: 18468702
references.citation: Trends Neurosci. 2002 Jun;25(6):295-301
references.pmid: 12086747
references.citation: Eur Arch Psychiatry Clin Neurosci. 2007 Aug;257(5):250-60
references.pmid: 17401728
references.citation: Science. 2003 Aug 8;301(5634):805-9
references.pmid: 12907793
references.citation: Am J Psychiatry. 2005 Jun;162(6):1179-87
references.pmid: 15930067
references.citation: Annu Rev Neurosci. 1999;22:105-22
references.pmid: 10202533
references.citation: Eur Arch Psychiatry Neurol Sci. 1985;235(3):171-8
references.pmid: 3879219
references.citation: Trends Cogn Sci. 2009 Nov;13(11):456-63
references.pmid: 19819753
references.citation: Clin Psychol Rev. 2001 Feb;21(1):33-61
references.pmid: 11148895
references.citation: J Manag Care Pharm. 2007 Nov;13(9 Suppl A):S3-11
references.pmid: 18062736
references.citation: Behav Brain Res. 2009 Jan 30;197(1):31-40
references.pmid: 18722480
references.citation: Mol Psychiatry. 2008 Feb;13(2):119-21
references.pmid: 18202694
references.citation: Neuropsychopharmacology. 2008 May;33(6):1312-22
references.pmid: 17609676
references.citation: Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11032-7
references.pmid: 11005874